Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$18.71
▲ $0.43 (+2.4%)
Market data updated: 09/21 09:26 AM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
Not available
Day Range
$18.06 - $18.81
52-Week Range
$9.49 - $19.26
Beta
—
Next Earnings
28.10.2026
Support
$16.56
Resistance
$19.26
AMRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+90.7% (1Y)
Strengths: 20/32 factors positiveRisk: Low
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 157.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $8.79 vs. price $18.71 (-53.0%)
Fair Value
Signal tension
Growth scores strong (73/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
68
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $18.71
Evidence: Euphoria score crossed 55 (now 56)
What happened after
Still awaiting outcome
today · $18.71
Evidence: FOMO score jumped from 7 to 53 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 21, 2026
Then
68
$18.71
Now
68
$18.71
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
73
Quality
63
Value
33
Momentum
88
Risk
70
Sentiment
100
Fundamental
52
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Amneal Pharmaceuticals (AMRX) has focused on its strong financial performance and strategic expansion. The company reported a 9.9% year-over-year revenue increase in Q2 2026, reaching $796.2 million, alongside raised full-year earnings guidance. Analysts noted a modest fair value increase, reflecting optimism over growth and new product launches. Additionally, Amneal completed its acquisition of Kashiv BioSciences, reinforcing its push into biosimilars and positioning itself as a leader in affordable medicines. The company also filed a shelf registration for up to $522.69 million in shares, signaling potential investments in future growth.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Amneal Pharmaceuticals, Inc.. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
51
🎯 Conviction (vs. Emotion)
42
Psychology
56
Fundamentals
52
Technical
88
Valuation
33
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+15%
Market Narrative
83
Fundamental Reality
42
Narrative Gap
+41
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **Herding** state (65) reflects relative underperformance today, where AMRX lagged peers (-2.4% vs. -1.9%), consistent with traders aligning with broader sector trends. Elevated **Overconfidence** (45) and **Euphoria** (36) scores—driven by extreme valuation (+98% over DCF)—suggest some investors remain optimistic despite weak momentum. The **narrative-reality gap** (20-point divergence) hints at a disconnect between market expectations and fundamentals. The key question: Will traders prioritize valuation over momentum, or will the gap widen further?
Updated: 09/07/2026, 07:04 AM
What could change this?
👥 What the crowd believes
"completed its acquisition of Kashiv BioSciences, a pivotal step in the company’s push to become America’s top Affordable Medicines company"
"reported a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year"
"analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models"
"filed a shelf registration for up to US$522.69 million of Class A common shares"
🧠 Market Brain events driving this
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 86/100
🔴 Weakest match
Samuel Armstrong Nelson — 9/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between methodologies, with some legendary investors seeing strong potential while others flag significant risks. Samuel Armstrong Nelson and Peter Lynch both rate it near the top, with Nelson emphasizing a favorable cycle position and Lynch spotting growth undervaluation—both classic signals for aggressive, forward-looking strategies. Meanwhile, Walter Bagehot and Gerald M. Loeb lean toward stability, praising liquidity and capital preservation, reflecting a cautious, defensive approach. At the opposite end, Benjamin Graham and Philip Fisher dismiss it outright, with Graham calling it a defensive failure and Fisher lacking the quality/growth traits he demanded. The middle ground is crowded: Howard Marks and the efficient-market duo see mixed signals, while Charles Mackay and Jack Schwager detect crowd behavior or indecision. This spectrum reveals a clash between growth hunters, value preservers, and skeptics—each methodology’s lens shapes whether they see a hidden gem, a speculative bubble, or a risky bet.
Peter Lynch
One Up on Wall Street (1989)
🟢 86
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 74
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 70
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 40
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 40
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 36
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 33
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 30
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 24
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 9
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A trading range after an advance, but still without clear (volume-based) confirmation of a distribution phase.
Low confidence
$16.56
Range Bottom
$19.26
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
36.9%
Operating Margin
13.1%
Net Margin
2.4%
EBITDA Margin
13.1%
ROE
-101.8%
ROA
2.0%
ROIC
—
EPS
$0.23
Cash
$282.03M
Total Debt
$2.57B
Current Ratio
2.17
Debt/Equity
-36.33
How is Fair Value calculated? →
Current Price
$18.71
Estimated Fair Value (DCF)
$8.79
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-53.0%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
11.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 11.0% | $299.59M | $274.85M |
| 2 | 8.9% | $326.16M | $274.52M |
| 3 | 6.7% | $348.15M | $268.84M |
| 4 | 4.6% | $364.25M | $258.04M |
| 5 | 2.5% | $373.35M | $242.65M |
Base FCF (last actual year)
$269.93M
Terminal Value
$5.89B
Present Value of Terminal Value
$3.83B
Enterprise Value
$5.15B
Net Debt
$2.29B
Equity Value
$2.86B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$0.22
Tangible Book Value per Share (Tangible NAV)
-$3.79
Sentiment based on basic keywords (not AI) — 13 positive, 7 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 15.9.2026
Benzinga · 9.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 5.9.2026
Insider Monkey · 4.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
Yahoo · 4.9.2026
Benzinga · 3.9.2026
Yahoo · 3.9.2026
StockStory · 3.9.2026
Yahoo · 27.8.2026
Yahoo · 27.8.2026
Yahoo · 26.8.2026
Zacks · 26.8.2026
Amneal Pharmaceuticals, Inc. (AMRX) currently has a StockIQ AI score of 68/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AMRX currently scores 68/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AMRX's estimated fair value is $8.79, which is 53.0% below the current price of $18.71. This is one valuation model among several signals in the fair-value category, not a price target.
AMRX's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 157.9%; Net income growth: 161.6%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Estimated fair value: $8.79 vs. price $18.71 (-53.0%); Return on equity (ROE): -101.8% (negative); P/E: 85.0.
StockIQ has no recorded dividend payment history for AMRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| BOYER ANDREW S | Gift | 1.9.2026 | 80,000 | -80,000 | — |
| BOYER ANDREW S | Gift | 21.8.2026 | 273,646 | -152,426 | — |
| BOYER ANDREW S | Gift | 21.8.2026 | 152,426 | -152,426 | — |
| Kiely John | Open Market Sale | 13.8.2026 | 50,000 | -50,000 | $17.64 |
| Kiely John | Gift | 13.8.2026 | 10,000 | -10,000 | — |
| Kiely John | Open Market Sale | 13.8.2026 | 210,252 | -50,000 | $17.64 |
| Kiely John | Gift | 13.8.2026 | 200,252 | -10,000 | — |
| Daly Jason B. | Open Market Sale | 12.8.2026 | 210,000 | -210,000 | $17.40 |
| Shah Nikita | Open Market Sale | 12.8.2026 | 146,403 | -146,403 | $17.51 |
| Shah Nikita | Open Market Sale | 12.8.2026 | 253,390 | -146,403 | $17.51 |
| Daly Jason B. | Open Market Sale | 12.8.2026 | 35,171 | -210,000 | $17.40 |
| Daly Jason B. | Open Market Sale | 11.8.2026 | 6,613 | -6,613 | $17.70 |
| BUCHI J KEVIN | Exercise of Derivative Securities | 11.8.2026 | 168,573 | -168,573 | $17.18 |
| BUCHI J KEVIN | Exercise of Derivative Securities | 11.8.2026 | 93,499 | -168,573 | $17.18 |
| Daly Jason B. | Open Market Sale | 11.8.2026 | 245,171 | -6,613 | $17.70 |
| Patel Chirag K. | Grant/Award from Employer | 10.8.2026 | 6,381,734 | +6,381,734 | — |
| Patel Chintu | Grant/Award from Employer | 10.8.2026 | 6,381,734 | +6,381,734 | — |
| Patel Tushar Bhikhubhai | Grant/Award from Employer | 10.8.2026 | 12,763,469 | +12,763,469 | — |
| Patel Gautam | Grant/Award from Employer | 10.8.2026 | 283,632 | +283,632 | — |
| Patel Tushar Bhikhubhai | Grant/Award from Employer | 10.8.2026 | 61,341,678 | +12,763,469 | — |
| Patel Chirag K. | Grant/Award from Employer | 10.8.2026 | 6,381,734 | +6,381,734 | — |
| Patel Chintu | Grant/Award from Employer | 10.8.2026 | 6,381,734 | +6,381,734 | — |
| Patel Gautam | Grant/Award from Employer | 10.8.2026 | 283,632 | +283,632 | — |
| Autor Deborah M. | Open Market Sale | 11.5.2026 | 34,819 | -34,819 | $12.94 |
| Autor Deborah M. | Open Market Sale | 11.5.2026 | 93,660 | -34,819 | $12.94 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
10,571,834 shares short as of 2026-08-31 · vs. 8,320,187 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.2% of trading volume this week was short selling, vs. 61.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology